13.12.2013 • NewsJohnson & JohnsonNovartisFentanyl

EU Fines Drugmakers €16 million for Painkiller Delay

The European Commission has fined U.S. pharmaceutical producer Johnson & Johnson (J&J) €10.8 million and Swiss drugmaker Novartis of Switzerland € 5.5 million for actions taken by the two companies' Dutch subsidiaries to delay market cheaper generic version of the painkiller fentanyl in the Netherlands in 2005.

Commission vice president Joaquín Almunia, who oversees EU competition policy, said J&J paid Novartis to delay the generic drug - a painkiller 100 times more potent than morphine - thus depriving cancer patients from access to a cheaper version.

Alumina noted that the U.S. drugmaker's patent production on the fentanyl depot patch had expired in the Netherlands, and Novartis' Sandoz arm was preparing to launch its generic fentanyl depot patch there. Rather than sell the generic version, Almunia said Sandoz instead signed a co-promotion agreement with J&J's Dutch subsidiary Janssen-Cilag, providing for monthly payments exceeding the profits it could expect from the generic product.

In December 2006, when a third party was about to launch a generic version, the Commission said the "anticompetitive agreement, which infringed Article 101 of the Treaty on the functioning of the European Union (TFEU),"was canceled.

The decision should make pharmaceutical companies think twice before engaging into such anticompetitive practices that harm both patients and taxpayers, Alumnia said, adding that the EU is "actively investigating 'pay-for-delay' agreements that limit generic entry in return for a value transfer by the originator company to the generic company."

In June of this year, the Commission adopted a proposal for a directive that it said would make it easier for victims of anticompetitive practices to obtain damages.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.